myasthenia gravis

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50 joint venture will be focused on developing nephrology pipeline utilizing Evotec’s UK kidney biobank, NURTuRE. Under the terms of the a...

Myasthenia gravis (MG) is an autoimmune syndrome that causes weakness in the skeletal muscles caused due to the failure of neuromuscular transmission. Communication between nerve cells and muscles becomes hampered, thus preventing crucial muscles from contracting. This impairment in results from the binding of auto...

Myasthenia Gravis June is Myasthenia Gravis Awareness Month. Myasthenia gravis is a disorder causing weakness and easy fatigue of voluntary muscles. It is caused by a breakdown in the communication between nerves and muscles, usually because of an immunological problem.

https://www.slideshare.net/DelveInsight/myasthenia-gravis-126250701?qid=b9adbccf-6d91-4e5e-84e1-7603c87a029e&v=&b=&from_search=1 Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved i...

Novo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...